We recognize that success in biologics is critical to the future pipelines of our potential partners. Our growing pipeline and intellectual property position in the field of Adnectins™ and PROfusion™ provide us with the opportunity to enter into alliances with other pharmaceutical companies to expand our commercial and therapeutic reach.

We believe in select, strategic relationships that rigorously strive towards create highly competitive medicines.

We encourage leading biopharmaceutical companies with world class biology and a strong track record of success to join our Adnexus team with hands on experiences in over 50 products, as well as alliance experiences with many leading pharmaceutical companies.

In 2007, we entered into a strategic alliance with Bristol Myers Squibb Company (BMS) to commercialize Adnectin-based therapeutics. The goal of the collaboration is to discover and develop Adnectin compounds specifically tuned to modulate oncology targets of high clinical impact. This alliance includes up to 6 programs based on 4 targets in oncology.

For more information on partnering please contact us at (781) 891-3745 or at info@adnexustx.com